By the beginning of next year, Biden will have received four million COVID treatments.


By January, Biden will have received four million COVID treatments.

By the end of January, the Biden administration could have received 4 million COVID treatments, including new antiviral pills that could be approved as soon as Wednesday.

Officials from the Obama administration told Bloomberg News that as the Omicron variant spreads, they are beefing up their COVID treatment arsenal.

A monoclonal antibody product, immunocompromised people’s pre-exposure preventive drugs, and the new antiviral pills that the FDA is expected to approve today are among the treatments.

The administration has sought to purchase a variety of FDA-approved therapeutics in order to have a variety of effective treatments, according to officials.

The Centers for Disease Control and Prevention (CDC) released data Monday night showing that Omicron is now responsible for 73% of COVID cases in the United States.

Last week’s data was also revised, with the share of the variant rising from 2.9 percent to 12.6 percent.

This means that the prevalence of the variant increased sixfold from week to week.

It has surpassed the Delta variant, which had been the dominant strain in the country since July.

The president announced on Tuesday that the government would send out 500 million at-home COVID tests in the new year, prompting long lines for testing across the country.

He also advised people to get vaccinated, boost their immune systems, and not to be alarmed.

‘This is not March 2020,’ Biden stated emphatically.

The FDA approved AstraZeneca Plc’s Evusheld, a pre-exposure prevention treatment for the immunocompromised and others who do not respond well to vaccines, earlier this month.

According to Bloomberg, the administration plans to allocate another 300,000 courses of GlaxoSmithKline Plc’s monoclonal antibody treatment by the end of January, and is in talks to purchase 600,000 more.

The FDA is expected to approve Paxlovid by Pfizer Inc. and molnupiravir by Merck & Co. this week.

According to the officials, the US should have nearly 400,000 courses of Merck’s pill and 65,000 courses of Pfizer’s pill available upon approval.

The government expects to receive about 3 million Merck courses – the entirety of its order – and 250,000 Pfizer courses by the end of January, according to officials.

The approval of these pills could have a significant impact on how Covid is treated.

They’re both highly effective – though some question molnupiravir’s ability to combat Omicron – and, unlike other effective treatments like monoclonal antibodies, they don’t necessitate a lot of resources to…

Nokia News in a Nutshell


Comments are closed.